Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature. 2001. 410: 1107-1111.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.

J Immunol. 2018 Aug 1;201(3):827-831. No abstract available.

PMID:
30038035
2.

Selected renal cells modulate disease progression in rodent models of chronic kidney disease via NF-κB and TGF-β1 pathways.

Bruce AT, Ilagan RM, Guthrie KI, Rivera E, Choudhury S, Sangha N, Spencer T, Bertram TA, Jain D, Kelley RW, Basu J.

Regen Med. 2015;10(7):815-39. doi: 10.2217/rme.15.43. Epub 2015 Nov 16.

PMID:
26568079
3.

Formulation of selected renal cells for implantation into a kidney.

Halberstadt C, Robbins N, McCoy DW, Guthrie KI, Bruce AT, Knight TA, Payne RG.

Methods Mol Biol. 2013;1001:279-87. doi: 10.1007/978-1-62703-363-3_23.

PMID:
23494437
4.

Phenotypic analysis of bioactive cells for application in regenerative medicine.

Burnette TB, Bruce AT.

Methods Mol Biol. 2013;1001:115-32. doi: 10.1007/978-1-62703-363-3_10.

PMID:
23494424
5.

Ex vivo culture and separation of functional renal cells.

Bruce AT, Guthrie KI, Kelley R.

Methods Mol Biol. 2013;1001:53-64. doi: 10.1007/978-1-62703-363-3_6.

PMID:
23494420
6.

Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.

Wang Y, Bruce AT, Tu C, Ma K, Zeng L, Zheng P, Liu Y, Liu Y.

J Cell Sci. 2011 Nov 1;124(Pt 21):3568-80. doi: 10.1242/jcs.084053. Epub 2011 Nov 1.

7.

Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.

Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ.

J Immunol. 2011 Jul 1;187(1):538-52. doi: 10.4049/jimmunol.1100450. Epub 2011 May 25.

8.

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis.

Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT.

J Immunol. 2011 Jul 1;187(1):490-500. doi: 10.4049/jimmunol.1100123. Epub 2011 May 23.

9.

Expansion of the human adipose-derived stromal vascular cell fraction yields a population of smooth muscle-like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells.

Basu J, Genheimer CW, Guthrie KI, Sangha N, Quinlan SF, Bruce AT, Reavis B, Halberstadt C, Ilagan RM, Ludlow JW.

Tissue Eng Part C Methods. 2011 Aug;17(8):843-60. doi: 10.1089/ten.tec.2010.0697. Epub 2011 May 19.

PMID:
21595545
10.

Functional evaluation of primary renal cell/biomaterial neo-kidney augment prototypes for renal tissue engineering.

Basu J, Genheimer CW, Rivera EA, Payne R, Mihalko K, Guthrie K, Bruce AT, Robbins N, McCoy D, Sangha N, Ilagan R, Knight T, Spencer T, Wagner BJ, Jayo MJ, Jain D, Ludlow JW, Halberstadt C.

Cell Transplant. 2011;20(11-12):1771-90. doi: 10.3727/096368911X566172. Epub 2011 Mar 24.

PMID:
21439130
11.

Increased urothelial cell detection in the primary bladder smooth muscle cell cultures with dual MACS/qRT-PCR approach.

Genheimer CW, Guthrie KI, Shokes JE, Bruce AT, Quinlan SF, Sangha N, Ilagan RM, Basu J, Burnette T, Ludlow JW.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):184-9. doi: 10.1097/PAI.0b013e3181f09311.

PMID:
20930617
12.

Isolation, characterization, and expansion methods for defined primary renal cell populations from rodent, canine, and human normal and diseased kidneys.

Presnell SC, Bruce AT, Wallace SM, Choudhury S, Genheimer CW, Cox B, Guthrie K, Werdin ES, Tatsumi-Ficht P, Ilagan RM, Kelley RW, Rivera EA, Ludlow JW, Wagner BJ, Jayo MJ, Bertram TA.

Tissue Eng Part C Methods. 2011 Mar;17(3):261-73. doi: 10.1089/ten.TEC.2010.0399. Epub 2010 Oct 27.

PMID:
20846053
13.

Tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in rodent model of chronic kidney disease.

Kelley R, Werdin ES, Bruce AT, Choudhury S, Wallace SM, Ilagan RM, Cox BR, Tatsumi-Ficht P, Rivera EA, Spencer T, Rapoport HS, Wagner BJ, Guthrie K, Jayo MJ, Bertram TA, Presnell SC.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1026-39. doi: 10.1152/ajprenal.00221.2010. Epub 2010 Sep 8.

14.

Molecular dissection of psoriasis: integrating genetics and biology.

Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP.

J Invest Dermatol. 2010 May;130(5):1213-26. doi: 10.1038/jid.2009.319. Epub 2009 Oct 8. Review.

15.

Use of iodixanol self-generated density gradients to enrich for viable urothelial cells from nonneurogenic and neurogenic bladder tissue.

Bruce AT, Sangha N, Richmond A, Johnson K, Jones S, Spencer T, Ludlow JW.

Tissue Eng Part C Methods. 2010 Feb;16(1):33-40. doi: 10.1089/ten.TEC.2009.0012.

PMID:
19351240
16.

Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.

Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT, Zou W.

J Immunol. 2008 Oct 1;181(7):4733-41.

17.

Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection.

Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD.

J Interferon Cytokine Res. 2006 Nov;26(11):804-19.

PMID:
17115899
18.

Interferon-gamma and cancer immunoediting.

Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD.

Immunol Res. 2005;32(1-3):231-45. Review.

PMID:
16106075
19.

Allogeneic cell therapy for the treatment of liver disease.

Ludlow JW, Bruce AT, Kulik MJ, Meheux SO, McCoy DW, Asfeldt TM.

Prog Transplant. 2005 Jun;15(2):178-84. Review.

PMID:
16013468
20.

A critical function for type I interferons in cancer immunoediting.

Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD.

Nat Immunol. 2005 Jul;6(7):722-9. Epub 2005 Jun 12. Erratum in: Nat Immunol. 2005 Aug;6(8):852.

PMID:
15951814
21.

Cancer immunoediting: from immunosurveillance to tumor escape.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.

Nat Immunol. 2002 Nov;3(11):991-8. Review.

PMID:
12407406
22.

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.

Nature. 2001 Apr 26;410(6832):1107-11.

PMID:
11323675
23.
24.

Sustained expression of human factor VIII in mice using a parvovirus-based vector.

Chao H, Mao L, Bruce AT, Walsh CE.

Blood. 2000 Mar 1;95(5):1594-9.

26.

Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Davidson MG, Lappin MR, Rottman JR, Tompkins MB, English RV, Bruce AT, Jayawickrama J.

Antimicrob Agents Chemother. 1996 Jun;40(6):1352-9.

27.

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.

Huang AY, Bruce AT, Pardoll DM, Levitsky HI.

Immunity. 1996 Apr;4(4):349-55.

28.

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

Huang AY, Bruce AT, Pardoll DM, Levitsky HI.

J Exp Med. 1996 Mar 1;183(3):769-76.

Supplemental Content

Loading ...
Support Center